Suppr超能文献

亚洲超高肾功能患者的非维生素 K 拮抗剂口服抗凝剂。

Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function.

机构信息

From the Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Republic of Korea (S.-R.L., E.-K.C., M.-J.C., S.O.).

Department of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea (K.-D.H., J.-H.J.).

出版信息

Stroke. 2019 Jun;50(6):1480-1489. doi: 10.1161/STROKEAHA.118.024264. Epub 2019 May 14.

Abstract

Background and Purpose- In clinical trials, the reduced efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention was reported for patients with nonvalvular atrial fibrillation with a creatinine clearance (CrCl) >95 mL/min compared with that of warfarin. We examined the effectiveness, safety, and net clinical benefit of NOACs compared with warfarin in Asian patients with atrial fibrillation and supranormal renal function. Methods- Using data from the Korean National Health Insurance Service database from January 2014 to December 2016, we included patients with nonvalvular atrial fibrillation with CrCl >80 mL/min. Among these incident oral anticoagulant users with rivaroxaban (n=6297), dabigatran (n=4241), apixaban (n=3395), edoxaban (n=1187), and warfarin (n=9884) were analyzed. Propensity score weighting was used to balance covariates across study groups. Hazard ratios for ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause death, and the composite outcome defined as ischemic stroke+intracranial hemorrhage+gastrointestinal bleeding+all-cause death were analyzed using Cox regression analysis with warfarin as the reference. Results- Baseline characteristics were well balanced among all groups (mean age, 66±11 years; 63% were men; mean CHADS-VASc score, 3.0±1.8). Forty-five percent of the patients had CrCl >95 mL/min. Pooled NOACs yielded lower risks of ischemic stroke (hazard ratio, 0.51; 95% CI, 0.43-0.60) and the composite outcome (hazard ratio, 0.64; 95% CI, 0.58-0.70) than warfarin in patients with CrCl >80 mL/min. These benefits were consistent in those with CrCl >95 mL/min. All 4 NOACs reduced the risks of ischemic stroke and the composite outcome in both patients with CrCl >80 mL/min and >95 mL/min. Conclusions- The NOACs showed better effectiveness and safety than warfarin in the patients with atrial fibrillation and supranormal renal function; this was consistently observed for all 4 NOACs and in patients with CrCl >95 mL/min.

摘要

背景与目的- 在临床试验中,与华法林相比,非维生素 K 拮抗剂口服抗凝剂(NOACs)在肌酐清除率(CrCl)>95mL/min 的非瓣膜性心房颤动患者中的卒中预防效果降低。我们检查了 NOACs 与亚洲心房颤动和肾功能超正常患者的华法林相比的有效性、安全性和净临床获益。方法- 使用 2014 年 1 月至 2016 年 12 月期间韩国国家健康保险服务数据库的数据,我们纳入了 CrCl>80mL/min 的非瓣膜性心房颤动患者。在这些新使用口服抗凝剂的患者中,瑞伐沙班(n=6297)、达比加群(n=4241)、阿哌沙班(n=3395)、依度沙班(n=1187)和华法林(n=9884)进行了分析。采用倾向评分加权法使研究组之间的协变量平衡。采用 Cox 回归分析,以华法林为参照,分析缺血性卒中、颅内出血、胃肠道出血、大出血、全因死亡和定义为缺血性卒中+颅内出血+胃肠道出血+全因死亡的复合结局的风险比。结果- 所有组的基线特征均很好地平衡(平均年龄 66±11 岁;63%为男性;平均 CHADS-VASc 评分 3.0±1.8)。45%的患者 CrCl>95mL/min。与华法林相比,混合的 NOACs 降低了 CrCl>80mL/min 患者的缺血性卒中(风险比 0.51;95%CI 0.43-0.60)和复合结局(风险比 0.64;95%CI 0.58-0.70)的风险。在 CrCl>95mL/min 的患者中,这些获益是一致的。所有 4 种 NOACs 均降低了 CrCl>80mL/min 和>95mL/min 的患者的缺血性卒中风险和复合结局风险。结论- 在肾功能超正常的心房颤动患者中,与华法林相比,NOACs 显示出更好的疗效和安全性;这在所有 4 种 NOACs 和 CrCl>95mL/min 的患者中均观察到。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验